{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:05:34Z","timestamp":1783926334895,"version":"3.55.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22577009"],"award-info":[{"award-number":["22577009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.119004","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:24:10Z","timestamp":1780298650000},"page":"119004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual-target antibacterial agents: Bridging molecular relationships to synergistic mechanisms"],"prefix":"10.1016","volume":"316","author":[{"given":"Yong-Zan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1309-8521","authenticated-orcid":false,"given":"Jian-Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119004_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119004_bib2","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108550","article-title":"Multitarget antibacterial drugs: an effective strategy to combat bacterial resistance","volume":"252","author":"Feng","year":"2023","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119004_bib4","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3390\/pharmaceutics14081749","article-title":"Fluoroquinolones hybrid molecules as promising antibacterial agents in the fight against antibacterial resistance","volume":"14","author":"Lungu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119004_bib5","series-title":"WHO Releases New Reports on New Tests and Treatments in Development for Bacterial Infections","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119004_bib6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119004_bib7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3343\/alm.2024.0522","article-title":"In-vitro activities of zoliflodacin and solithromycin against Neisseria gonorrhoeae isolates from Korea","volume":"45","author":"Roh","year":"2025","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.ejmech.2026.119004_bib9","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1021\/acsinfecdis.4c00438","article-title":"Interactions between zoliflodacin and Neisseria gonorrhoeae gyrase and topoisomerase IV: enzymological basis for cellular targeting","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1092556","article-title":"\u03b2-Lactam potentiators to re-sensitize resistant pathogens: discovery, development, clinical use and the way forward","volume":"13","author":"Narendrakumar","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/ph14050420","article-title":"Mutation-based antibiotic resistance mechanism in methicillin-resistant Staphylococcus aureus clinical isolates","volume":"14","author":"Ali","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119004_bib12","article-title":"Mechanisms of antibiotic resistance","volume":"4","author":"Munita Jose","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.ejmech.2026.119004_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrmicro3155","article-title":"Ribosome-targeting antibiotics and mechanisms of bacterial resistance","volume":"12","author":"Wilson","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1128\/MMBR.00016-10","article-title":"Origins and evolution of antibiotic resistance","volume":"74","author":"Davies","year":"2010","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/pathogens14080777","article-title":"Resistance of gram-negative bacteria to cefepime-enmetazobactam: a systematic review","volume":"14","author":"Falagas","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.ejmech.2026.119004_bib16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/antibiotics11091215","article-title":"The mechanism of bacterial resistance and potential bacteriostatic strategies","volume":"11","author":"Zhang","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2026.119004_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1675682","article-title":"Precision bacterial immunotherapy: an integrated mechanistic taxonomy and translational roadmap against antimicrobial resistance","volume":"16","author":"Al-Azzani","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119004_bib18","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.cell.2020.05.005","article-title":"A dual-mechanism antibiotic kills gram-negative bacteria and avoids drug resistance","volume":"181","author":"Martin","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119004_bib19","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1021\/acsinfecdis.0c00001","article-title":"Multitarget approaches against multiresistant superbugs","volume":"6","author":"Gray","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib20","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1038\/s41467-025-62407-4","article-title":"A broad-spectrum antibiotic targets multiple-drug-resistant bacteria with dual binding targets and no detectable resistance","volume":"16","author":"He","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119004_bib21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.coph.2008.06.008","article-title":"How many modes of action should an antibiotic have?","volume":"8","author":"Br\u00f6tz-Oesterhelt","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119004_bib22","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/17460441.2010.508069","article-title":"Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance","volume":"5","author":"Pokrovskaya","year":"2010","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119004_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112931","article-title":"Polypharmacological drug actions of recently FDA approved antibiotics","volume":"209","author":"Wetzel","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1039\/C7NP00006E","article-title":"Bifunctional antimicrobial conjugates and hybrid antimicrobials","volume":"34","author":"Klahn","year":"2017","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2026.119004_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127514","article-title":"Structural hybridization as a facile approach to new drug candidates","volume":"30","author":"Sampath Kumar","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119004_bib26","doi-asserted-by":"crossref","first-page":"19470","DOI":"10.1039\/D2RA03281C","article-title":"Design and synthesis of hybrid compounds as novel drugs and medicines","volume":"12","author":"Alkhzem","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119004_bib27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1039\/D4MD00934G","article-title":"Recent advancements in the development of next-generation dual-targeting antibacterial agents","volume":"16","author":"Sofi","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics","volume":"22","author":"Miller","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib29","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01831-13","article-title":"Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections","volume":"58","author":"Locher Hans","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","article-title":"Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance","volume":"65","author":"Chopra","year":"2001","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib31","article-title":"Mechanistic insights into synergistic effects using coupled PK-PD modeling","volume":"15","author":"Sun","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119004_bib32","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1517\/13543784.6.10.1479","article-title":"Dual \u03b2-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatment","volume":"6","author":"Bryskier","year":"1997","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.119004_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.33.7.1067","article-title":"Mode of action of the dual-action cephalosporin Ro 23-9424","volume":"33","author":"Georgopapadakou","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1128\/AAC.33.6.944","article-title":"Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime","volume":"33","author":"Jones","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib36","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/AAC.34.10.1895","article-title":"Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals","volume":"34","author":"Christenson","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ja.2008.80","article-title":"Exploring the positional attachment of Glycopeptide\/\u03b2-lactam heterodimers","volume":"61","author":"Long","year":"2008","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2026.119004_bib39","author":"Sader"},{"key":"10.1016\/j.ejmech.2026.119004_bib40","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1128\/AAC.00712-12","article-title":"TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections","volume":"56","author":"Stryjewski Martin","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib41","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1128\/AAC.06274-11","article-title":"In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of corynebacterium species","volume":"56","author":"Tyrrell Kerin","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib42","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1128\/AAC.05532-11","article-title":"Antistaphylococcal activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic","volume":"56","author":"Blais","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib46","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/jac\/dkv300","article-title":"Susceptibility of Clostridium difficile isolates from a phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection","volume":"71","author":"Gerding","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkt411","article-title":"In Vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection","volume":"69","author":"Chilton","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib48","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jac\/dkt401","article-title":"Cadazolid, a novel antibiotic with potent activity against clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses","volume":"69","author":"Baldoni","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib49","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1128\/AAC.00504-15","article-title":"Multicenter, double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection","volume":"59","author":"Louie","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-3099(18)30614-5","article-title":"Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials","volume":"19","author":"Gerding","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02077-16","article-title":"In vitro activities of MCB3681 and eight comparators against Clostridium difficile isolates with known ribotypes and diverse geographical spread","volume":"61","author":"Freeman","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib52","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.anaerobe.2014.07.001","article-title":"In Vitro activity of MCB3681 against Clostridium difficile strains","volume":"28","author":"Rashid","year":"2014","journal-title":"Anaerobe"},{"key":"10.1016\/j.ejmech.2026.119004_bib53","doi-asserted-by":"crossref","first-page":"767.e761","DOI":"10.1016\/j.cmi.2015.05.025","article-title":"Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle","volume":"21","author":"Dalhoff","year":"2015","journal-title":"Clin. Microbiol. Infection"},{"key":"10.1016\/j.ejmech.2026.119004_bib57","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1128\/AAC.01649-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus","volume":"52","author":"Robertson Gregory","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib58","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/AAC.01651-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci","volume":"52","author":"Robertson Gregory","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib60","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1021\/acs.jmedchem.6b00485","article-title":"Development of a dual-acting antibacterial agent (TNP-2092) for the treatment of persistent bacterial infections","volume":"59","author":"Ma","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib59","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1021\/acs.jmedchem.1c02045","article-title":"Design, synthesis, and characterization of TNP-2198, a dual-targeted rifamycin-nitroimidazole conjugate with potent activity against microaerophilic and anaerobic bacterial pathogens","volume":"65","author":"Ma","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib61","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1473-3099(24)00003-3","article-title":"Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials","volume":"24","author":"Li","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib62","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/ofid\/ofw172.1788","article-title":"Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in patients with acute bacterial skin and soft structure infections from a phase 2 randomized, adaptive-design, dose-ranging study","volume":"3","author":"O'Riordan","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib63","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib64","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib33","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2174\/092986707780831168","article-title":"Dual action-based approaches to antibacterial agents","volume":"14","author":"John","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib37","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/ja.2008.79","article-title":"A multivalent approach to drug discovery for novel antibiotics","volume":"61","author":"Long","year":"2008","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2026.119004_bib43","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","article-title":"Antibiotics in the clinical pipeline in October 2019","volume":"73","author":"Butler","year":"2020","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2026.119004_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1158152","article-title":"Bifunctional antibiotic hybrids: a review of clinical candidates","volume":"14","author":"Koh","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119004_bib45","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1021\/acs.chemrestox.0c00524","article-title":"Nonclinical evaluation of antibacterial oxazolidinones contezolid and contezolid acefosamil with low serotonergic neurotoxicity","volume":"34","author":"Wang","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119004_bib54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41589-020-00715-0","article-title":"Structure of Erm-modified 70S ribosome reveals the mechanism of macrolide resistance","volume":"17","author":"Svetlov","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119004_bib55","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119004_bib56","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins \u2013 obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2026.119004_bib65","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ejmech.2017.11.082","article-title":"4-Quinolone derivatives and their activities against gram positive pathogens","volume":"143","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103291","article-title":"Recent advances in the synthetic and medicinal perspective of quinolones: a review","volume":"92","author":"Dhiman","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112222","article-title":"Design, synthesis and structure-activity relationships of novel 15-membered macrolides: quinolone\/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides","volume":"193","author":"Fan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib68","doi-asserted-by":"crossref","first-page":"8566","DOI":"10.1016\/j.bmc.2010.10.024","article-title":"Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials","volume":"18","author":"Pavlovi\u0107","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/ml100253p","article-title":"Discovery of 4\u2032\u2032-Ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity","volume":"2","author":"Pavlovi\u0107","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119004_bib70","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1128\/AAC.00524-16","article-title":"Macrolones are a novel class of macrolide antibiotics active against key resistant respiratory pathogens in Vitro and in vivo","volume":"60","author":"\u010cip\u010di\u0107 Paljetak","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.6023\/cjoc202506020","article-title":"Structural modifications, structure-activity relationships, and total synthesis advances in erythromycin analogs against resistant pathogens","volume":"46","author":"Xinyi Cui","year":"2026","journal-title":"Chin. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib72","series-title":"Ether Linked Macrolides Useful for the Treatment of Microbial Infections","author":"Alihodzic","year":"2006"},{"key":"10.1016\/j.ejmech.2026.119004_bib73","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41589-024-01685-3","article-title":"Macrolones target bacterial ribosomes and DNA gyrase and can evade resistance mechanisms","volume":"20","author":"Aleksandrova","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119004_bib74","doi-asserted-by":"crossref","first-page":"10496","DOI":"10.1073\/pnas.1103474108","article-title":"Role of antibiotic ligand in nascent peptide-dependent ribosome stalling","volume":"108","author":"V\u00e1zquez-Laslop","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib75","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41421-024-00702-y","article-title":"Synthetic macrolides overcoming MLSBK-Resistant pathogens","volume":"10","author":"Ma","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.ejmech.2026.119004_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116630","article-title":"Design, synthesis and structure-activity relationships of novel non-ketolides: 9-oxime clarithromycin featured with seven-to thirteen-atom-length diamine linkers at 3-OH","volume":"276","author":"Ma","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107712","article-title":"Design and structure-activity relationships of ether-linked alkylides: hybrids of 3-O-descladinosyl macrolides and quinolone motifs","volume":"151","author":"Zhang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib78","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.2174\/15680266113136660223","article-title":"Structure-activity relationships and mechanism of action of macrolides derived from erythromycin as antibacterial agents","volume":"13","author":"Jian-Hua","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib79","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1021\/jm980240d","article-title":"Synthesis and antibacterial activity of ketolides (6-O-methyl-3- oxoerythromycin derivatives): a new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens","volume":"41","author":"Agouridas","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118562","article-title":"Dual-targeting ketolide-quinolone hybrids overcome erm-mediated resistant pathogens via ribosomal and DNA gyrase inhibition","volume":"305","author":"Liu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109396","article-title":"4\u2033-modified azithromycin derivatives bearing nitrogen-containing heterocycles with dual inhibitory activity","volume":"169","author":"Martynov","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib82","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2007.04.005","article-title":"The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria","volume":"26","author":"Leach","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119004_bib83","doi-asserted-by":"crossref","first-page":"13339","DOI":"10.1073\/pnas.0804276105","article-title":"The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning","volume":"105","author":"Wilson","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib84","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/AAC.05702-11","article-title":"Resistance to linezolid caused by modifications at its binding site on the ribosome","volume":"56","author":"Long","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib85","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1093\/jac\/dkac263","article-title":"Oxazolidinones: mechanisms of resistance and Mobile genetic elements involved","volume":"77","author":"Brenciani","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib86","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0968-0896(03)00083-X","article-title":"Design, synthesis and biological evaluation of oxazolidinone\u2013quinolone hybrids","volume":"11","author":"Hubschwerlen","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib87","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/j.bmcl.2003.07.021","article-title":"Novel oxazolidinone\u2013quinolone hybrid antimicrobials","volume":"13","author":"Gordeev","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119004_bib88","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1016\/j.bmcl.2003.07.028","article-title":"Structure\u2013activity relationship in the oxazolidinone\u2013quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action","volume":"13","author":"Hubschwerlen","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119004_bib89","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3390\/molecules24081641","article-title":"Synthesis, antibacterial activities, mode of action and acute toxicity studies of new oxazolidinone-fluoroquinolone hybrids","volume":"24","author":"Liu","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119004_bib90","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1021\/cr0301088","article-title":"Molecular insights into aminoglycoside action and resistance","volume":"105","author":"Magnet","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1074-5521(99)80006-4","article-title":"Prodigious substrate specificity of AAC(6')-APH(2\"), an aminoglycoside antibiotic resistance determinant in enterococci and staphylococci","volume":"6","author":"Daigle","year":"1999","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119004_bib92","doi-asserted-by":"crossref","first-page":"9846","DOI":"10.1021\/bi049135y","article-title":"Domain\u2212Domain interactions in the aminoglycoside antibiotic resistance enzyme AAC(6')-APH(2'')","volume":"43","author":"Boehr","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2026.119004_bib93","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/CMR.16.3.430-450.2003","article-title":"Versatility of aminoglycosides and prospects for their future","volume":"16","author":"Vakulenko Sergei","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib94","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/jm900028n","article-title":"Design, synthesis, and evaluation of novel fluoroquinolone\u2212aminoglycoside hybrid antibiotics","volume":"52","author":"Pokrovskaya","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib95","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.bmc.2017.02.068","article-title":"Covalently linked kanamycin \u2013 ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance","volume":"25","author":"Shavit","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib96","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1021\/acs.jmedchem.6b00867","article-title":"Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux","volume":"59","author":"Gorityala","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib97","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijantimicag.2013.11.001","article-title":"Evaluation of Galleria mellonella larvae for measuring the efficacy and pharmacokinetics of antibiotic therapies against Pseudomonas aeruginosa infection","volume":"43","author":"Hill","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2026.119004_bib98","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1099\/jmm.0.074245-0","article-title":"A Galleria mellonella infection model reveals double and triple antibiotic combination therapies with enhanced efficacy versus a multidrug-resistant strain of Pseudomonas aeruginosa","volume":"63","author":"Krezdorn","year":"2014","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib99","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1126\/science.1099390","article-title":"Bacterial persistence as a phenotypic switch","volume":"305","author":"Balaban","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119004_bib100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrmicro1557","article-title":"Persister cells, dormancy and infectious disease","volume":"5","author":"Lewis","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib101","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1073\/pnas.0711712105","article-title":"Single-cell protein induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria","volume":"105","author":"Gefen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119004_bib102","first-page":"704","article-title":"The importance of being persistent: heterogeneity of bacterial populations under antibiotic stress","volume":"33","author":"Gefen","year":"2009","journal-title":"FEMS (Fed. Eur. Microbiol. Soc.) Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib103","doi-asserted-by":"crossref","first-page":"6191","DOI":"10.1128\/JB.01651-09","article-title":"Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis","volume":"192","author":"Mulcahy Lawrence","year":"2010","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2026.119004_bib104","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1002\/chem.201303310","article-title":"New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy","volume":"20","author":"Trevi\u00f1o","year":"2014","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2026.119004_bib105","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01967563","article-title":"Structure, biochemistry and mechanism of action of glycopeptide antibiotics","volume":"8","author":"Reynolds","year":"1989","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejmech.2026.119004_bib106","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/ja.2014.111","article-title":"Glycopeptide antibiotics: back to the future","volume":"67","author":"Butler","year":"2014","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2026.119004_bib107","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bmcl.2018.11.038","article-title":"Synthesis and evaluation of biological activity for dual-acting antibiotics on the basis of azithromycin and glycopeptides","volume":"29","author":"Tevyashova","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119004_bib108","doi-asserted-by":"crossref","first-page":"5196","DOI":"10.1016\/j.ejmech.2011.08.001","article-title":"Novel C-4\u2033 modified azithromycin analogs with remarkably enhanced activity against erythromycin-resistant streptococcus pneumoniae: the synthesis and antimicrobial evaluation","volume":"46","author":"Ma","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib109","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.bmcl.2009.01.092","article-title":"Synthesis and antibacterial activity of 4\u2033,11-di-O-arylalkylcarbamoyl azithromycin derivatives","volume":"19","author":"Ma","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119004_bib110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ja.2009.108","article-title":"Synthesis and antibacterial activity of novel 11,12-cyclic carbonate azithromycin 4\u2033-O-carbamate derivatives","volume":"63","author":"Ma","year":"2010","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2026.119004_bib111","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10069","article-title":"Metabolite-enabled eradication of bacterial persisters by aminoglycosides","volume":"473","author":"Allison","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119004_bib112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/mr.51.3.341-350.1987","article-title":"Mechanism of bactericidal action of aminoglycosides","volume":"51","author":"Davis","year":"1987","journal-title":"Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib113","doi-asserted-by":"crossref","first-page":"8786","DOI":"10.1021\/nn502201a","article-title":"Engineering persister-specific antibiotics with synergistic antimicrobial functions","volume":"8","author":"Schmidt","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejmech.2026.119004_bib114","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1074-5521(02)00153-9","article-title":"Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding A site","volume":"9","author":"Vicens","year":"2002","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119004_bib115","doi-asserted-by":"crossref","first-page":"8278","DOI":"10.1021\/ja051722z","article-title":"A simple structural-based approach to prevent aminoglycoside inactivation by bacterial defense proteins. Conformational restriction provides effective protection against Neomycin-B nucleotidylation by ANT4","volume":"127","author":"Asensio","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119004_bib116","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7164\/antibiotics.30.893","article-title":"Aminoglycoside antibiotics: synthesis of 5''-amino-5''-deoxyneomycin and 5''-amino-5''-deoxyparomomycin","volume":"30","author":"Hanessian","year":"1977","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.ejmech.2026.119004_bib117","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/antibiotics10040390","article-title":"Binding and action of triphenylphosphonium analog of chloramphenicol upon the bacterial ribosome","volume":"10","author":"Chen","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2026.119004_bib118","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/antibiotics10050489","article-title":"Triphenilphosphonium analogs of chloramphenicol as dual-acting antimicrobial and antiproliferating agents","volume":"10","author":"Pavlova","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2026.119004_bib119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/152165401317291183","article-title":"Transfer of cationic antibacterial agents berberine, palmatine, and benzalkonium through bimolecular planar phospholipid film and Staphylococcus aureus membrane","volume":"52","author":"Severina","year":"2001","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2026.119004_bib120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/antibiotics12010015","article-title":"Conjugates of chloramphenicol amine and berberine as antimicrobial agents","volume":"12","author":"Pavlova","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2026.119004_bib121","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/antibiotics11070970","article-title":"Activation of a bacterial mechanosensitive channel, MscL, underlies the membrane permeabilization of dual-targeting antibacterial compounds","volume":"11","author":"Wray","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2026.119004_bib122","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1021\/jm501082n","article-title":"Design, synthesis, and antibacterial properties of dual-ligand inhibitors of Acetyl-CoA carboxylase","volume":"57","author":"Silvers","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib123","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1021\/cb9000102","article-title":"Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches","volume":"4","author":"Mochalkin","year":"2009","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119004_bib124","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1073\/pnas.0811275106","article-title":"A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore","volume":"106","author":"Miller","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119004_bib126","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1080\/14756366.2020.1755852","article-title":"Bacterial \u03b9-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium Burkholderia territorii","volume":"35","author":"Del Prete","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib127","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1080\/14756366.2022.2092729","article-title":"Structure-activity relationship studies for inhibitors for vancomycin-resistant enterococcus and human carbonic anhydrases","volume":"37","author":"An","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib128","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acsmedchemlett.3c00032","article-title":"Evaluation of 1,3,4-Thiadiazole carbonic anhydrase inhibitors for gut decolonization of vancomycin-resistant enterococci","volume":"14","author":"Abutaleb","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119004_bib129","article-title":"In vivo antibacterial activity of acetazolamide","volume":"65","author":"Abutaleb Nader","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/antibiotics12010142","article-title":"Carbonic anhydrase inhibitors as novel antibacterials in the era of antibiotic resistance: where are we now?","volume":"12","author":"Nocentini","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ejmech.2026.119004_bib131","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.4155\/fmc-2021-0207","article-title":"Bacterial carbonic anhydrases: underexploited antibacterial therapeutic targets","volume":"13","author":"P Flaherty","year":"2021","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib132","doi-asserted-by":"crossref","first-page":"19077","DOI":"10.1021\/acs.jmedchem.4c01555","article-title":"Inhibition of Pseudomonas aeruginosa carbonic anhydrases, exploring ciprofloxacin functionalization toward new antibacterial agents: an In-Depth multidisciplinary study","volume":"67","author":"Marinacci","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117620","article-title":"Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant Enterococci","volume":"291","author":"Ammara","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib134","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1021\/acs.jmedchem.8b01878","article-title":"Discovery of lipophilic bisphosphonates that target bacterial cell wall and quinone biosynthesis","volume":"62","author":"Malwal","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1073\/pnas.1219899110","article-title":"Antibacterial drug leads targeting isoprenoid biosynthesis","volume":"110","author":"Zhu","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib136","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1016\/j.bmc.2011.05.042","article-title":"4-Alkoxy-3-arylfuran-2(5H)-ones as inhibitors of tyrosyl-tRNA synthetase: synthesis, molecular docking and antibacterial evaluation","volume":"19","author":"Xiao","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib137","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1016\/j.bmc.2014.05.018","article-title":"Novel 3-arylfuran-2(5H)-one-fluoroquinolone hybrid: design, synthesis and evaluation as antibacterial agent","volume":"22","author":"Wang","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119004_bib138","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119004_bib139","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41586-022-05019-y","article-title":"Teixobactin kills bacteria by a two-pronged attack on the cell envelope","volume":"608","author":"Shukla","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119004_bib140","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1128\/AAC.01050-16","article-title":"Dual targeting of cell wall precursors by teixobactin leads to cell lysis","volume":"60","author":"Homma","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib141","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1039\/C8SC02616E","article-title":"Probing key elements of teixobactin-lipid II interactions in membranes","volume":"9","author":"Wen","year":"2018","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib142","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1126\/science.abn4213","article-title":"Bioinformatic prospecting and synthesis of a bifunctional lipopeptide antibiotic that evades resistance","volume":"376","author":"Wang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119004_bib143","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401793","article-title":"Dual-mechanism peptide SR25 has broad antimicrobial activity and potential application for healing bacteria-infected diabetic wounds","volume":"11","author":"Luo","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib144","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1038\/s41467-023-42374-4","article-title":"Targeting nucleic acid phase transitions as a mechanism of action for antimicrobial peptides","volume":"14","author":"Sneideris","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119004_bib145","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02340-16","article-title":"Intracellular targeting mechanisms by antimicrobial peptides","volume":"61","author":"Le","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.119004_bib146","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/978-981-13-3588-4_6","article-title":"Intracellular antimicrobial peptides targeting the protein synthesis machinery","volume":"1117","author":"Graf","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119004_bib147","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.actbio.2024.12.002","article-title":"Aggregation-prone antimicrobial peptides target gram-negative bacterial nucleic acids and protein synthesis","volume":"192","author":"Chen","year":"2025","journal-title":"Acta Biomater."},{"key":"10.1016\/j.ejmech.2026.119004_bib148","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41579-019-0322-2","article-title":"Drug resistance and tolerance in fungi","volume":"18","author":"Berman","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib149","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41579-021-00511-0","article-title":"Treatment strategies for cryptococcal infection: challenges, advances and future outlook","volume":"19","author":"Iyer","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib150","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41579-023-00960-9","article-title":"The rapid emergence of antifungal-resistant human-pathogenic fungi","volume":"21","author":"Lockhart","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib151","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41564-020-0767-0","article-title":"Dual-mechanism antibiotics","volume":"5","author":"Theuretzbacher","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib152","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.aaa6097","article-title":"How to bolster the antifungal pipeline","volume":"347","author":"Denning","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119004_bib153","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41564-024-01662-5","article-title":"A dual-targeting antifungal is effective against multidrug-resistant human fungal pathogens","volume":"9","author":"Zhou","year":"2024","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2026.119004_bib154","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1021\/ja044205+","article-title":"Amphiphilic polymethacrylate derivatives as antimicrobial agents","volume":"127","author":"Kuroda","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119004_bib155","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nbt1267","article-title":"Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies","volume":"24","author":"Hancock","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119004_bib156","doi-asserted-by":"crossref","first-page":"13155","DOI":"10.1073\/pnas.1507893112","article-title":"Helical antimicrobial polypeptides with radial amphiphilicity","volume":"112","author":"Xiong","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib157","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41467-019-08868-w","article-title":"Helical antimicrobial peptides assemble into protofibril scaffolds that present ordered dsDNA to TLR9","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119004_bib158","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","article-title":"Antimicrobial host defence peptides: functions and clinical potential","volume":"19","author":"Mookherjee","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119004_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202108501","article-title":"Histidine-mediated ion specific effects enable salt tolerance of a pore-forming marine antimicrobial peptide","volume":"61","author":"Xian","year":"2022","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119004_bib160","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1039\/D2CS00395C","article-title":"Unnatural helical peptidic foldamers as protein segment mimics","volume":"52","author":"Sang","year":"2023","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib161","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1021\/ct301097u","article-title":"Noncovalent interactions of DNA bases with naphthalene and graphene","volume":"9","author":"Cho","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2026.119004_bib162","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1002\/anie.202000505","article-title":"Poly(2-Oxazoline)-Based functional peptide mimics: eradicating MRSA infections and persisters while alleviating antimicrobial resistance","volume":"59","author":"Zhou","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119004_bib163","doi-asserted-by":"crossref","first-page":"11030","DOI":"10.1021\/acs.chemrev.0c01074","article-title":"Functional DNA-polymer conjugates","volume":"121","author":"Whitfield","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib164","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2026.119004_bib165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119004_bib166","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cell.2022.05.009","article-title":"BacPROTACs mediate targeted protein degradation in bacteria","volume":"185","author":"Morreale","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119004_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104656","article-title":"Antibacterial PROTACs: the road ahead for next-generation antibiotics?","volume":"31","author":"Milelli","year":"2026","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119004_bib168","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tibs.2025.12.012","article-title":"BacPROTAC-induced protein degradation as a new antibiotic concept","volume":"51","author":"Junker","year":"2026","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2026.119004_bib169","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1038\/s41467-024-48506-8","article-title":"Targeted protein degradation in mycobacteria uncovers antibacterial effects and potentiates antibiotic efficacy","volume":"15","author":"Won","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119004_bib170","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41570-021-00313-1","article-title":"Towards the sustainable discovery and development of new antibiotics","volume":"5","author":"Miethke","year":"2021","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.ejmech.2026.119004_bib171","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202414325","article-title":"Fighting antimicrobial resistance: innovative drugs in antibacterial research","volume":"64","author":"S\u00fcssmuth","year":"2025","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2026.119004_bib172","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cell.2020.04.001","article-title":"A deep learning approach to antibiotic discovery","volume":"181","author":"Stokes","year":"2020","journal-title":"Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:13:50Z","timestamp":1783923230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":172,"alternative-id":["S0223523426004496"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119004","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-target antibacterial agents: Bridging molecular relationships to synergistic mechanisms","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119004"}}